A Phase 1 interventional study of COVID-19 vaccine, low dose level and COVID-19 vaccine, high dose level in COVID19, Sars-Cov-2, sponsored by Rokote Laboratories Finland Oy. Completed at 1 site in Finland. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Rokote Laboratories Finland Oy · Phase 1, Interventional, and Prevention
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 40 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Rokote Laboratories Finland Oy is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Subjects with prior vaccination with at least two doses of any COVID-19 vaccine
Biological: COVID-19 vaccine, low dose level · Other: Nasal Drops
Subjects with prior vaccination with at least two doses of any COVID-19 vaccine
Biological: COVID-19 vaccine, low dose level · Other: Nasal Spray
Subjects with prior vaccination with at least two doses of any COVID-19 vaccine
Biological: COVID-19 vaccine, high dose level · Other: Nasal Drops
Subjects with prior vaccination with at least two doses of any COVID-19 vaccine
Biological: COVID-19 vaccine, high dose level · Other: Nasal Spray
Subjects with no prior COVID-19 vaccination - COULD NOT BE RECRUITED
Biological: COVID-19 vaccine, high dose level · Other: Nasal Drops
Subjects with no prior COVID-19 vaccination - COULD NOT BE RECRUITED
Biological: COVID-19 vaccine, high dose level · Other: Nasal Spray
Test article
Also known as: COV2
Test article
Also known as: COV2
Method of administration of test article
Method of administration of test article
Primary Immunogenicity
Percentage of subjects demonstrating a rise in SARS-CoV-2 serum NAb titers against Omicron BA.5 variant
Time frame: 28 days from baseline
Primary Safety
Treatment-emergent expected and unexpected adverse effects
Time frame: 28 days from baseline
Secondary Immunogenicity
Percentage of subjects demonstrating a rise in SARS-CoV-2 serum NAb titers against Wuhan and JN.1 variants
Time frame: 28 days from baseline
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rokote Laboratories Finland Oy